Genprex, Inc. · NASDAQ:GNPX
Genprex — Investor Presentation (April 2026)
64 slides from Genprex's investor presentation, Apr 21, 2026
Slide 1: Pioneering Gene Therapies for Patients in Need
€) Genprex’ Pioneering Gene Therapies for Patients in Need April 2026
Slide 2: Forward-Looking Statements
Forward-Looking Statements Satermentconaine inthis presenti egaring atest are it isi a a “awarding stalarets wa the meaning ofthe Pree Seeies gato Reloem Atal 1065, Gece ach tsetse bjork ana uncaanies awal eas mayer mawraly fmt epresed er ipledbysuchfewardlocking statements Sud steers inue ut arere.
Slide 3: Our Mission
Our Mission Advancing novel gene therapies for patients afflicted with cancer or diabetes. © Genprex
Slide 4: Program Highlights
Program Highlights ONCOLOGY DIABETES @) Non-viral gene therapy platform @) Addressing both Type 1 and Type 2 diabetes with AAV gene therapy Novel approach using systemic gene therapy to replace tumor suppressor genes for cancerin _ (@) Novel infusion process delivers genes to pancreas humans ae Demo
Slide 5: Research and Development Pipeline
Research and Development Pipeline ft = rset ° So a © Genprex
Slide 6: Oncology
Q ONCOLOGY REPROGRAMMING THE COURSE OF CANCER Cry} www.genprex.com
Slide 7: Why TUSC2?
Why TUSC2? Discovery —° Tumor Suppressor Candidate 2 —— Chromosome 3p213 deleted gene ——° Previously called FUS1 ——e NPRL2 is in the same area of the chromosome © Genprex: Tumor Suppressor Gene TUSC2 restoration in cancer cells invvitro inhibits cell growth and induces apoptosis © TUSC2 is encoded b
Slide 8: Tumor Suppressor Genes Deleted During Cancer Development
Tumor Suppressor Genes Deleted During Cancer Development ——* Tumor suppressor genes are deleted early during cancer development ——» 82% of all non-small cell lung cancers and 100% of all small-cell tung cancers ‘express decreased amounts of TUSC2 ‘tumor suppressor protein ————# Loss or reduction of
Slide 9: Oncoprex Non-viral Delivery System
Oncoprex® Non-viral, positively-charged lipid-based nanoparticle in a lipoplex form is systemically Delivery System delivered. NON-VIRAL DELIVERY OF TUMOR SUPPRESSOR GENE EQORSA® Gone Therapy © Genprex: Cationic lipoplex carries drug to tumors.
Slide 10: Our Cancer Treatment Approach
Our Cancer Treatment Approach Tumor suppressor genes are deleted early during cancer development. Our method of treating cancer is to reintroduce tumor suppressor genes to patients. © Genprex ‘Tumor Suppressor Gene in a DNA Plasmid We have rights to cu have cancer-fighaing, expressed in a DNA f Non-
Slide 11: Systemic Gene Therapy Platform
Systemic G Th Platte % Moyet even to yer ncoprex® Delivery System rea ancer Genes Allows for delivery of TUSC2 and NPRL2 genes and potentially a variety of other genes Synergies Can be used jn combination with other cancer therapies such as Tagrisso® and Tecentrig® Cancers Data indicate it could com
Slide 12: Reqorsa Targets Cancer At Its Core
Regorsa® Targets Cancer At Its Core Controls Cell Signaling Tyrosine kinase inhibition decreases cancer cel proliferation © Genprex Stimulates Apoptotic Pathways Leads to programmed cancer cell death Muttiple anti-cancer mechanisms of action. ~*~ Modulates Immune Response Promotes immune activity ag
Slide 13: Reqorsa Reduces Glycolysis in Cancer Cells
® -_ Reqorsa® Reduces Glycolysis in REQORSA Reverses Fundamental Cancer Cells Cancers are detected by PET scans + PET scanning is based on increased glucose uptake in cancer cells + Due to high rate of glycolysis in cancer cells + Increased glycolysis is found in virtually all cancers. A549 cells ar
Slide 14: Lung Cancer: By the Numbers
Lung Cancer: By the Numbers 124K $104B 28% e e oe @ U.S. Annual Global Lung Global U.S. Lung U.S. Average Mortality Cancer Incidence Market Cancer Incidence —_ Lung Cancer Survival More than Morethan two milion Globalmarket isprojected More than 229,000 new Rate deaths ‘new cases per year to grow fr
Slide 15: Reqorsa Monotherapy ONC-001 Trial
Regorsa® Monotherapy ONC-001 Trial DOSE ESCALATION STUDY Explored toxicity and tolerability in patients. Phase 1 monotherapy results: + 31 Stage IV Lung cancer patients + 0.01 - 0.09 mg/kg + 23 patients evaluable + 5 patients had stable disease + 2patients had tumor shrinkage + Generally well-tolera
Slide 16: Selective Uptake of Reqorsa
Selective Uptake REQORSA Targets Cancer Cells of Regorsa Pretreatment Biopsies Posttreatment Biopsies REQORSA is det functioning TUSC2 ancer cells while minimizing its uptake by normal tissue. Patient 1 (02 moka = Patient 2 reatment. (06 mo/to) > © Genprex
Slide 17: Reqorsa + Tarceva ONC-002 Phase 1/2 Trial
® Regorsa® + Tarceva ONC-002 Phase 2 Trial Met Simon 2-stage criteria to enroll the full 39 subjects, but was discontinued to start study with Tagrisso. ene — ome 2 ee Ueinomn Omi} © seve os, ‘ee > ihe = a fey cam 2 ser ote oom : 2 tein Uno come ‘ OGenprex:
Slide 18: Addressing drug resistance to Tagrisso and Tecentriq
For most patients, drug resistance to Tagrisso® and Tecentriq® is inevitable.!23 Our approach is designed to address drug resistance. “© REQORSA Immunogene Therapy may be complementary with targeted drugs and immunotherapies. ® REQORSA's multimodal activity may block emerging bypass pathways, thereb
Slide 19: Reqorsa + Tagrisso Reduce Tumor Growth in Resistant Tumors
Regorsa® + Tagrisso Reduce Tumor Growth in Tagrisso Resistant Tumors Enhanced Anti-Tumor Activity 0s C2 combinatior on REQORSA in combination with Tagrisso demonstrated significantly increased anti-tumor efficacy in EGFR mutant Tagrisso resistant NSCLC tumors in H1975- OsiR mouse xenografts. + con o
Slide 20: Acclaim-1: Reqorsa + Tagrisso for NSCLC
» Patients with advanced, EGFR mutant NSCLC whose disease progressed after Tagrisso® monotherapy or Tagrisso® combination therapy © FDA Fast Track Designation > ~10-15US. sites © ~119 patients © Phase 1 Dose Escalation: 12 patients (completed) © Phase 2a Expansion: ~33 patients (eurrently enrolling)
Slide 21: Phase 1 Dose Escalation Safety and Efficacy
Phase 1 Dose Escalation Excellent safety profile and efficacy ep eed patent O06 mans OBB mBRG ZMK Tot we on n ue » iil alco ig ig aa Delayed intision-Related Reaction a a Besta note abet + Nosymptoms during 30 min infusion Cee ciebicatnne diched + Fever, chills, and muscle aches. mae + Symptoms gene
Slide 22: Reqorsa in Small Cell Lung Cancer
Regorsa® in Small Cell Lung Cancer Targeting Small Cell Lung Cancer (in addition to NSCLC} allows Genprex to address virtually the entire lung cancer market. ‘Small Cell Lung Cancer: —— Consistently has low TUSC2 protein levels + Documented to often have deletion of at least one TUSC2 gene allele. —
Slide 23: SCLCs Express Low Levels of TUSC2 Protein
SCLCs Express Low Levels Of TUSC2 Protein IHC analysis of tumor specimens Since all SCLCs have reduced or no TUSC2 —— 41% of SCLC have no TUSC2 protein expression protein expression, re-expressing TUSC2 100% of SCLC have reduced or no TUSC2 protein protein may lead to clinical efficacy. expression t
Slide 24: Tecentriq SCLC Approval Trial
Tecentrig® (atezolizumab) ; SCLC Approval Trial i i i IMpower133 Study ‘Adding Tecentriq to standard therapy improves survival in SCLC and establishes a new standard therapy for ES-SCLC. © Untreated, extensive stage SCLC ——* Carboplatin & etoposide chemotherapy + atezolizumab or placebo + A ccycles,
Slide 25: Atezolizumab Maintenance Therapy
Atezolizumab Maintenance Therapy Once patients begin maintenance therapy with Tecentriq, Progression Free Survival is very 4a short (2.6 mos). Unstratinos HR 086 (5% Ct: 052-038) ——° Atezolizumab vs placebo + AUWCR, PR. and SD patients received maintenance therapy Endpoints measured from the start o
Slide 26: Reqorsa Adds Significantly to Tecentriq Treatment
Regorsa® Adds Significantly to H41 SCLC call xenografts Tecentriq Treatment in humanized mice CONTROL REQORSA REQORSA + Heai scLc - TECENTRIQ Aad xo REQORSA
Slide 27: Increased Immune Response with Reqorsa and Tecentriq
Increased Immune Response with Regorsa® and Tecentriq OGenprex:
Slide 28: Acclaim-3: Reqorsa + Tecentriq for SCLC
© Patients with ES-SCLC who did not develop tumor progression after receiving Tecentriq® and chemotherapy © Fast Track Designation and Orphan Drug Designation 2 ~10-15US. sites © ~62 patients © Phase 1 Dose Escalation: {completed} © Phase 2: ~50 patients (currently enrolling) © Phase 2 interim analy
Slide 29: Reqorsa in Ras Inhibitor Resistant Lung Cancer
Regorsa® in Ras Inhibitor Resistant REQORSA effectively overcomes sotorasib AR in Lung Cancer KRASG12Cmutant NSCLC mouse xenografts Published Results: ‘+ Researchers demonstrated that REQORSA, alone cr in cembination + TUSC2 transfection significantly reduced colony with sotoresib inhibited colony f
Slide 30: Reqorsa in ALK-EML4 Positive Translocated Lung Cancer
Regorsa® in ALK-ELM4 Positive License Agreement and SRA with The University of Translocated Lung Cancer Michigan Rogel Cancer Center and Collaboration with ALK- Positive Advocacy Group Published Results: ALK-Positive Collaboration: REQORSA induces apoptosis in alectnib oN atient-deven research resis
Slide 31: Reqorsa in ALK Xenograft Model
Reqorsa® in ALK Xenograft Model NCI-H2228 xenograft REQORSA markedly decreases growth of ALK- wai sensitive xenografts in mice s * Both as single agent and in combination ra with alectinib 3 Regorsa + vehicle 788 contra BNP + alectinib 60.14 Regorsa + alectinib 7860 © Genprex
Slide 32: Reqorsa in Mesothelioma
Regorsa® in Mesothelioma Published Results: + Researchers investigated whether DEE Rassarchers demonstrated that TUSC? transfection could modulate REQORSA treatment resulted in: MPM aggressive properties + Significant decrease in colt + Four MPM cell ines and tert- proliferation, cell invasion, and
Slide 33: NPRL2 Induces Anti-tumor Activity in NSCLC
NPRL2 Induces wnizsPembreon ASI Lang Met Anti-tumor Activity in NSCLC poe Further Evidence of Oncoprex® Delivery System as a Platform for Treatment Using Tumor Suppressor Genes 0 Study investigated the antitumor responses to NPRL2 gene therapy on anti-PD1 resistant KRAS/STK11 mutant NSCLC ina humani
Slide 34: Combined TUSC2 and NPRL2 Re-Expression in SCLC
Combined TUSC2 and NPRL2 Re-Expression in SCLC TUSC2+NPRL2 Dual Gene Therapy Combination on Inflamed H841 Tumors in Hu-NSG Mice 3 tases wes H841 lacks both TUSC2 and NPRL2 protein = al te a 4 E Increased control of xenograft growth H ell P of compared to: aa e . + Control eae att + TUSC2 re-expressi
Slide 35: Diabetes
Q DIABETES
Slide 36: Diabetes: By the Numbers
Diabetes: By the Numbers 40M $37B e e e @ Diabetes U.S. Diabetes Global Global Diabetes. T2D Global Market T1D Global Market Prevalence? Prevalence? Expenditures? (17.2% CAGR®) 15M US. aduleshave Bpected © 10 859M by predlaberes. © Genprex
Slide 37: Diabetes can cause serious complications
© Genprex Diabetes can cause serious complications. In 2024, there was approximately 1 death every 9 seconds caused by diabetes worldwide.
Slide 38: Diabetes Causes Serious Complications
Diabetes Causes Serious Complications (9ee@ 0 Heart Disease Leading cause of death for men and women in US, Diabetics are 2x as likely o have heart disease or a stroke. Chronic Kidney Disease Approximately 1in3 adults with diabetes have CKD. Xldney alseases are the 9th leading cause of death in Us,
Slide 39: Diabetic Patients Are In Need of Advanced Therapy
Diabetic Patients Are In Need of Advanced Therapy telete of Langerhans Recombnar Prodice ins ard DNA techniques produce Syicrede 1978 1901 The most significant advancementin the treatment of diabetes happened in 1922 — more than 100 years ago. © Genprex a Potential for disease modification for long-
Slide 40: Novel Gene Therapy Diabetes Program
Novel Gene Therapy License Agreement and SRA with University Diabetes Program of Pittsburgh intends to address both T1D and T2D. 38M or 11.6% of Americans Have Diabetes? Type 1 Diabetes (5-10%) -———e °—_— Type 2 Diabetes (90-95%) ‘An autoimmune condition where the body's Immune system destroys pancr
Slide 41: GPX-002 Replenishes Insulin Producing Cells
GPX-002 Replenishes ee i * programs and restores Insulin Producing Cells cell function in T1D. Delivers Genes to the Pancreas ‘A novel infusion process uses an AAV vector deliver the 30 (Ph genes che pancreas, i Hyperglycemia Intraductal infusion ‘of Pd and Mofo ‘expressing AAV Reprograms Alpha Cell
Slide 42: Reversed Drug-Induced Diabetes in T1D Toxin-Induced Mouse Model
Reversed Drug-Induced Diabetes in T1D Toxin-Induced Mouse Model = ° Conot| —AAVE-GFP = AAV@-Pa ———*__ Reprogramed alpha cells into beta-like cells that appropriately produce insulin in response to glucose levels. — fa) Normalized blood glucose in beta cell-toxin-induced diabetie mice. Genprex
Slide 43: Restored Blood Glucose in T1D Autoimmune Mouse Model
Restored Blood Glucose in T1D In Autoimmune Mouse Model for Four Months 10 The duration of restored blood glucose levels in mice could potentially translate to decades in humans. © One week in a mouse tends to about one yeer in . ols .—- ice given syngeneic islet °F 0 2 4 6 0 0a sa te t0 m0 3a trans
Slide 44: Functional Insulin-Expressing Cells from Alpha Cells in Human Islets
Induced Generation of Functional Insulin-Expressing Cells from Alpha Cells in Human Islets Provides a potential basis for further investigation in human Type 1 diabetes © Human islets treated with streptozotocin bad to destroy beta-cells, then treated with either AAV-PM or AAV-GFP. 2 AAV treated isl
Slide 45: Non-Human Primate Model of T1D Reduced Insulin Requirements
Non-Human Primate Model of T1D Reduced Insulin Requirements © Genprex: vast ape NPE HI at —e NHP 2 Virat infusion 3 ass v2 lal +" hi Data from University of Pittsburgh researchers show a marked reduction in insulin requirements.
Slide 46: Decreased Insulin Requirements and Improved Glucose Tolerance in NHPs
Decreased Insulin Requirements and Improved Glucose Tolerance in NHPs Following the pancreatic intraductal infusion of the AAV engineered construct, the eight oo NHPs had: pidhcspesinet) ———— Decreased insulin requirements i aii t {p<0.001) ——— increased c-peptide levels, (p<0.05) —— Improved glucos
Slide 47: NHP2 Three-Month Glucose Tolerance Test
NHP2 Three-Month Glucose Tolerance Test E) “© Pre Gone Therapy {Post Gene Therapy (3 months) ‘Normal NHP 400 B 300 aceeege 3 ———. 200 2 6 f 100 _ ——s ° f ° 20 40 60 Time (min) © Genprex
Slide 48: IHC Eight Weeks After Gene Therapy
IHC Eight Weeks After Gene Therapy Need at least 20% of normal beta cell mass to maintain normoglycemia zZ Fel 3 3 5 2 a Normal NHP Diabetic NHP Without Gene Therapy Diabetic NHP After Gene Therapy Genprex’
Slide 49: Rejuvenates Exhausted Beta Cells in T2D NHP Models
Rejuvenates Exhausted Beta Cells in T2D NHP Models NHP 1 AAV infusion into the pancreatic duct Improved glucose tolerance testing over several months At seven months, NHP had normal glucose tolerance testing Decrease in insulin requirements, Intraductal infusion is superior to direct injection OGenp
Slide 50: Studying GPX-002 Using a Lipid Nanoparticle
Studying GPX-002 Using a ows ' iperias Uae Lipid Nanoparticle * Sere piers New studies use an alternative second generation approach with a non-viral id nanoparticle delivery system First and only company to research diabetes gene therapy using a lipid nanoparticle in place of a viral AAV May allow
Slide 51: Corporate
Q CORPORATE www.genprex.com
Slide 52: Our Team: Company Management
Our Team: Company Management an & i yan Confer, MS. Mark S Berger, MD Thomas Gallagher, JO President, Chit Execusive Office & Chit Medical fice Seni Vice Preddant, Chie Financial fee Suzanne Thornton-Jones, PHO Regulatory fare saci beset ings trough ne rep
Slide 53: Our Team: Scientific Advisory Board
Our Team: Scientific Advisory Board Jack A. Rath Tony S K Mok Pasi Antero anne George Simon George Gites MD, FACS, Chaleman MO, FRCRIC) FRAC, FHKAM MO, Pho MO NO Professor ard Protez cf Medie, rae Deparment of Medd nesogy the Harvard Mesa! Sno ‘slg at Advent Heath Hong Kong Co founder a the ‘etorof
Slide 54: Our Team: Clinical Advisory Board
Our Team: Clinical Advisory Board \ MenaetMerse Cot. George Peoples luge teres an
Slide 55: Our Team: Board of Directors
Our Team: Board of Directors
Slide 56: Achievements & Upcoming Milestones
Achievements & Upcoming Milestones Acclaim -1 Acclaim -3 DIABETES DISCOVERY
Slide 57: We believe in a future of transformational patient care
We believe in a future of transformational patient care. 21% Century Large Combination Two FDA Gene Markets & Trials with Top Fast Track Therapies Unmet Need | SellingDrugs | Designations Exploring New Indications & Partnerships
Slide 58: Appendix
Slide 59: References
Research References Slide 7 1. Wistuba Behrens G Vimani AK, eal High resalucion chromosome 3p lelocypng of uman lung cancer and preneoplasiipreinvasive bronchial épihellum reveals mulaple, deconanuous sites of 3p alelelossand chree egions of frequencbreakpoincs. Cancer Res 2000/50(7}1 949-1960, Slid
Slide 60: References
Research References Slide 36 1. Cencers for Disease Convo (2026) buns ibic Wasaga 2. tncemadonal Dabeces Federaton (2025) hash ivach7nd 3. IDF Dlabeces Adas (2025 hsUbiclys4sSP20% 4 Precedence Research: hansUinely/dbviscNy 5. Precedence Research: ansi/bx MidmaTOLN, Slide 37 1. Centers for Disease Co
Slide 61: Slide 61
Slide 62: Reqorsa + Keytruda Significantly Reduced Tumor Growth
Regorsa® + Keytruda® REQORSA increases immune response Significantly Reduced Tumor gates Hine cnc eneer at Growth The independent immunologic effects of REQORSA and Keytruda markedly decrease tumor growth by increasing the immunologic attack on the tumor compared to PD-1 inhibition alone. © Genprex
Slide 63: AACR 21: Reqorsa May Enhance First-Line Standard of Care
AACR 21: Regorsa® May Enhance First-Line Standard of Care Regorsa® + Keytruda® + Chemo ——* REQORSA enhances the efficacy of chemo-immunotherapy on KRAS-LKB1 (kL)-mutant lung metastases in humanized mice. Tota Fox) ———* Tripte combination demonstrated strong antitumor efficacy an robust antitumor imm
Slide 64: Acclaim-2: Reqorsa + Keytruda for NSCLC
Acclaim-2 is no Longer enrolling new patients. tt Soret Acelan 2 9 Patients with advanced NSCLC whose disease progressed after ‘treatment with Keytruda® * o FDA Fast Track Designation Regorsa!in combination with Merck & Co's Keytnuda® for NSCLC al . Phase 2b: Comparing Progression Free Survival of R